PHILADELPHIA, June 8, 2021 /PRNewswire/ --
FMC Corporation (NYSE: FMC), a leading agricultural sciences
company, received U.S. Environmental Protection Agency (EPA)
registration for fluindapyr, a novel broad-spectrum succinate
dehydrogenase inhibitor (SDHI) fungicide. Fluindapyr provides
broad-spectrum activity against a wide range of destructive
diseases in row and specialty crops, as well as turf.
"Fluindapyr is the result of nearly 10 years of research and
development," said Dr. Kathleen
Shelton, FMC vice president and chief technology officer.
"This is the first significant regulatory approval for this new
fungicide. To date, we have submitted for registration of
fluindapyr formulations in multiple countries, including
China, Brazil, Argentina, and the European Union, covering
key markets in every region."
Upon the grant of these registrations, farmers around the world
will have access to fluindapyr for preventative control of various
fungal diseases in row crops, including multiple rust diseases in
cereals and soybeans, as well as powdery mildew in specialty crops.
Studies show fluindapyr controls pathogens that are resistant to
other chemical classes.
In addition, golf course superintendents in the U.S. will have
the flexibility to tackle destructive diseases such as Bipolaris
Leaf Spot, Take-All Root Rot and Large Patch in warm-season turf,
as well as Anthracnose, Fairy Ring
and Dollar Spot in cool-season turfgrasses with FMC's new Kalida™
fungicide, a combination of fluindapyr and flutriafol.
Kalida™ fungicide fits extremely well in turfgrass disease
management programs, allowing superintendents to rotate chemistry
and achieve outstanding results. This offering follows the
company's highly successful launch of Rayora™ fungicide, a
stand-alone flutriafol product for use on golf course turf.
"We are excited to provide growers and golf course
superintendents with a valuable new fungicide active ingredient to
rotate into their disease management program," said Diane Allemang, FMC vice president and chief
marketing officer. "Broad-spectrum disease control is
important as multiple diseases can attack at the same time. Our
research demonstrates that fluindapyr is an effective fungicide
that is an excellent mixture partner to other fungicide active
ingredients and is compatible with best-in-class disease management
programs. FMC will bring to market high-performance fluindapyr
premixture products that provide flexible and versatile resistance
management with superior performance on key tough-to-control
diseases. FMC fluindapyr brands will provide growers across the
globe the flexibility and versatility to customize their programs
as they see fit, treat multiple crops and export their crops
freely."
About FMC
FMC Corporation, an agricultural sciences company, provides
innovative solutions to growers around the world with a robust
product portfolio fueled by a market-driven discovery and
development pipeline in crop protection, plant health, and
professional pest and turf management. This powerful combination of
advanced technologies includes leading insect control products
based on Rynaxypyr® and Cyazypyr® active
ingredients; Authority®, Boral®,
Centium®, Command® and
Gamit® branded herbicides;
Talstar® and Hero® branded
insecticides; and flutriafol-based fungicides. The FMC portfolio
also includes biologicals such as Quartzo® and
Presence® bionematicides. FMC Corporation employs
approximately 6,400 employees around the globe. To learn more,
please visit www.fmc.com.
FMC, the FMC logo, Rynaxypyr, Cyazypyr, Authority, Boral,
Centium, Command, Gamit, Talstar, Hero, Quartzo, Presence, Rayora
and Kalida are trademarks of FMC Corporation or an affiliate.
Always read and follow all label directions, restrictions and
precautions for use. Products listed here may not be registered for
sale or use in all states, countries or jurisdictions.
Hero® insecticide is a restricted use pesticide in
the United States.
Statement under the Safe Harbor Provisions of the Private
Securities Litigation Reform Act of 1995: FMC and its
representatives may from time to time make written or oral
statements that are "forward-looking" and provide other than
historical information, including statements contained herein, in
FMC's other filings with the SEC, and in reports or letters to FMC
stockholders.
In some cases, FMC has identified forward-looking statements
by such words or phrases as "will likely result," "is confident
that," "expect," "expects," "should," "could," "may," "will
continue to," "believe," "believes," "anticipates," "predicts,"
"forecasts," "estimates," "projects," "potential," "intends" or
similar expressions identifying "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995, including the negative of those words and phrases. Such
forward-looking statements are based on management's current views
and assumptions regarding future events, future business conditions
and the outlook for the company based on currently available
information. These statements involve known and unknown risks,
uncertainties and other factors that may cause actual results to be
materially different from any results, levels of activity,
performance or achievements expressed or implied by any
forward-looking statement. Currently, one of the most
significant factors is the potential adverse effect of the current
COVID-19 pandemic on the financial condition, results of
operations, cash flows and performance of FMC, which is
substantially influenced by the potential adverse effect of the
pandemic on FMC's customers and suppliers and the global economy
and financial markets. The extent to which COVID-19 impacts us will
depend on future developments, which are highly uncertain and
cannot be predicted with confidence, including the scope, severity
and duration of the pandemic, the actions taken to contain the
pandemic or mitigate its impact, and the direct and indirect
economic effects of the pandemic and containment measures, among
others. Additional factors include, among other things, the
risk factors and other cautionary statements included within FMC's
2020 Form 10-K filed with the SEC as well as other SEC filings and
public communications. Moreover, investors are cautioned to
interpret many of these factors as being heightened as a result of
the ongoing and numerous adverse impacts of the COVID-19
pandemic.
FMC cautions readers not to place undue reliance on any such
forward-looking statements, which speak only as of the date made.
Forward-looking statements are qualified in their entirety by the
above cautionary statement. FMC undertakes no obligation, and
specifically disclaims any duty, to update or revise any
forward-looking statements to reflect events or circumstances
arising after the date on which they were made, except as otherwise
required by law.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/fmc-corporations-fluindapyr-fungicide-receives-us-epa-registration-301307667.html
SOURCE FMC Corporation